65,437 trials
Melanoma
Primary: Disease Control Rate by Modified World Health Organization (mWHO) Tumor Assessment Criteria — 17.6; 4.8; 23.5; 9.5 Percentage of participants
Solid Tumors · High Grade Gliomas · Lung Cancer
Primary: Test Image and Retest Image Reproducibility of Fluciclatide Injection ([18F]AH111585) Uptake by Solid Tumors Following Intravenous Administration of AH111585 (18F)…
Mountain Sickness
Primary: Adverse Events. — 29; 40 Events
Asthma · GERD
Primary: Mean Change in Morning Peak Expiratory Flow (mPEF (L/Minute)) From Baseline (Mean of the Last 7 Days in the run-in Period) to Treatment Period (Mean of All Available…
Premature Infants
Primary: Protein — 3.1; 3.6 g/kg/d
Hereditary Angioedema
Primary: Time to Onset of Symptom Relief. — 2.0; 12.0 Hours — p=< 0.001
Otitis Media With Effusion
Primary: Device Success — 21 devices
Glaucoma
Primary: Data on Prescription Drug Renewals, Appointment Compliance and Medication Taking (e.g. Physician Notes) — 150; 152 participants
Migraine
Primary: Number of Subjects Reporting Headache Relief at the 2 Hour Post Treatment Assessment. Relief Was Measured as a 2-point Change on a 4-point Scale (0=None, 1=Mild…
Transtibial Amputation
Primary: Metabolic Oxygen Consumption During Ambulation — 3.45; 3.13; 2.97 Watts per kilogram
Attention-deficit/Hyperactivity Disorder
Primary: Percentage of Participants With Treatment Failures During the Double-Blind Randomized-Withdrawal Phase — 64.9; 49.3 percentage of treatment failures — p=0.006
Hernia
Primary: Analgesic Efficacy — 26.5; 32.3 percentage of patients with NRS≥4
Phase 1 Pharmacodynamic Study
Primary: Pharmacodynamic Effect of Oral Calcitonin — 37.5; 100; 41.2; 44.4 percentage of time-matched placebo respo
Depression · Anxiety · Posttraumatic Stress
Primary: Depression — -0.52; -1.02 units on a scale — p=<0.001
Liver Cancer
Primary: Percentage of Participants With Objective Response (OR) — 9.1 percentage of participants